Abstracts tagged "Dendritic cells"

Abstract Number: 97 • 2018 ACR/ARHP Annual Meeting
Enhanced IFN-α Production By Plasmacytoid Dendritic Cells Is Associated with Increased Toll-like Receptor 7 Retention in the Lysosomes and Exosure to Type I IFN in Systemic Lupus Erythematosus
Goh Murayama¹, Asako Chiba², Ayako Makiyama², Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake², ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Type I interferon(IFN) appears to contribute to the development of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes has been reported…
Abstract Number: 845 • 2018 ACR/ARHP Annual Meeting
New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation
Ram R. Singh, Miguel-Angel Gutierrez, Peter Kim, Darshan Randhawa, Rachael Philips, Jennifer K. King and Anna Eriksson, Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA
Background/Purpose: Acquired or self antigens in tissues are taken to lymphoid organs to elicit protective immunity or tolerance, respectively. This is accomplished by dendritic cells…
Abstract Number: 1018 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritis and Psoriatic Arthritis.
Viviana Marzaioli¹, Mary Canavan¹, Achilleas Floudas¹, Siobhan C. Wade¹, Candice Low², Douglas J. Veale² and Ursula Fearon¹, ¹Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland
Background/Purpose: Tofacinitib (Pfizer) is an oral Janus kinase inhibitor, recently approved for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Although its mechanism…
Abstract Number: 1022 • 2018 ACR/ARHP Annual Meeting
TNF-α Regulates Plasmacytoid Dendritic Cells By Suppressing IFN-α Production and Enhancing Th1 and Th17 Cell Differentiation
Antonios Psarras^1,2,3, Agne Antanaviciute⁴, Ian Carr⁴, Miriam Wittmann^1,2, Paul Emery^1,5, George C Tsokos⁶ and Edward M Vital^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, ⁴Leeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom, ⁵Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Human plasmacytoid dendritic cells (pDCs) play a vital role in modulating immune responses. pDCs can produce massive amounts of type I IFNs in response…
Abstract Number: 1023 • 2018 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells That Infiltrate the Lungs Produce Profibrotic Cytokines and Chemokines in Bleomycin-Induced Model of Systemic Sclerosis
Isela Valera¹ and Ram R. Singh², ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: In bleomycin-induced model of systemic fibrosis and patients with systemic sclerosis, plasmacytoid DC (pDC) are unaffected or reduced systemically (spleen/peripheral blood) but they increase…
Abstract Number: 1111 • 2018 ACR/ARHP Annual Meeting
CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis
Clarissa Corinaldesi¹, Yasser M El-Sherbiny², Gemma Migneco³, Rebecca Ross¹, Steve Holmes⁴, Clive McKimmie⁵ and Francesco Del Galdo¹, ¹Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, ⁴Capella Biosciences, LTD, London, United Kingdom, ⁵Virus Host Interactions Team, Section of Infection and Immunity, University of Leeds, Leeds, United Kingdom
Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete…
Abstract Number: 2082 • 2018 ACR/ARHP Annual Meeting
ERAP1 Deficiency Partially Relieves HLA-B27-Induced ER Stress and IL-23 Expression, but Does Not Restore Dendritic Cell Function in Experimental Spondyloarthritis
Tri Tran¹, Vance Holt², Tejpal Gill¹, Joshua R. Bennett², Joel Taurog³ and Robert Colbert⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX, ⁴National Institute of Arthritis and Musculuskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Preliminary results suggest that endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) deficiency partially protects HLA-B27/human b2m transgenic (B27-Tg) rats from spondyloarthritis (SpA) as evidenced by…
Abstract Number: 2121 • 2018 ACR/ARHP Annual Meeting
Serum High Type I Interferon Is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Plasmacytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney
Taro Iwamoto¹, Jessica M. Dorschner², Mark A. Jensen¹, Shanmugapriya Selvaraj³, Danielle Vsetecka², Shreyasee Amin², Ashima Makol², Floranne C. Ernste², Thomas Osborn², Kevin Moder², Vaidehi R. Chowdhary², Valeria Mezzano⁴, Peter M. Izmirly⁵, H. Michael Belmont⁵, Robert M. Clancy¹, Jill P. Buyon¹, Ming Wu³, Cynthia A. Loomis³ and Timothy B. Niewold¹, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Mayo Clinic College of Medicine, Rochester, MN, ³Department of Pathology, New York University, New York, NY, ⁴Division of Cardiology, New York University, New York, NY, ⁵Division of Rheumatology, New York University, New York, NY
Background/Purpose: Despite recent advancements in immunosuppressive therapies, lupus nephritis (LN) remains one of the most severe organ manifestations in systemic lupus erythematosus (SLE). High type…
Abstract Number: 1948 • 2017 ACR/ARHP Annual Meeting
TNF-α Overrides the Ability of RANK Ligand to Induce Osteoclast Differentiation of Classical Circulating Precursors
Cecilia Ansalone¹, Flavia Sunzini¹, Caitlin Duncan¹, Sabarinadh Chilaka¹, Iain B. McInnes² and Carl S. Goodyear³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: TNF-α is well known to be involved in inflammatory-induced bone destruction. This is widely supported by clinical studies showing reduced bone pathology after anti-TNF-α…
Abstract Number: 2576 • 2017 ACR/ARHP Annual Meeting
Caspase 8 in Dendritic Cells Suppresses IRF5 Activation through Endosomal TLR Signaling to Prevent SLE-like Disease
FuNien Tsai¹, Harris Perlman² and Carla Cuda², ¹Medicine-Rheumatology, Northwestern University-Feinberg School of Medicine, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the pathogenesis of systemic lupus erythematosus (SLE), yet the mechanisms underlying this involvement are not yet clear.…
Abstract Number: 2616 • 2017 ACR/ARHP Annual Meeting
Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus
Xinran Yuan¹, Dandan Wang² and Lingyun Sun³, ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School, nanjing, China
Background/Purpose: Several tolerogenic dendritic cell (DC) subsets have been identified in human such as CD1c+ DCs, which could be elevated by injection of Flt-3 ligand…
Abstract Number: 2704 • 2017 ACR/ARHP Annual Meeting
Skin Migratory Dendritic Cells Targeted and Tolerized By Calcitriol-Peptide Liposomes Supress Antigen-Specific Autoreactive T Cell Expansion and Memory Differentiation to Regulate Autoimmune Arthritis
Ryan Galea^1,2, Hendrik Nel^1,2, Meghna Talekar^1,2, Suzanne Cole³, Karyn Cochlin⁴, Shannon Hitchcock⁵, Bijun Zeng^1,2, Suman Yekollu^1,2, Jamie Rossjohn⁶, Hugh Reid⁷, Ravi Malaviya⁵, Dave Shealy⁸, Brendan O'Sullivan^1,2 and Ranjeny Thomas^1,2, ¹Dendright Pty Ltd, Brisbane, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³Immunology, Janssen Research and Development, Spring House, PA, ⁴Immunology, Janssen Research and Development, Springhouse, PA, ⁵Janssen Research and Development, Springhouse, PA, ⁶Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, ⁷Monash University, Melbourne, Australia, ⁸Janssen Research and Development, Spring House, PA
Background/Purpose: Current treatments to control autoimmune arthritis and vasculitis use broadly immunosuppressive drugs, associated with undesirable side effects. Antigen-specific immunological tolerance strategies are preferable to…
Abstract Number: 2776 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Anagha Divekar³, Rajan Saggar⁴, Dinesh Khanna⁵, Daniel E. Furst⁶ and Ram R. Singh⁷, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Biolegend, Sa Diego, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells…
Abstract Number: 4 • 2017 ACR/ARHP Annual Meeting
Downregulation of microRNAs in Plasmacytoid Dendritic Cells Is Associated with a Type I Interferon Signature in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Joel A.G. van Roon^2,3, Ruth D.E. Fritsch-Stork⁴, Cornelis P.J. Bekker¹, Aridaman Pandit¹, Marzia Rossato⁵ and Timothy R.D.J. Radstake¹, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Laboratory for Translational immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The most prominent alteration in the immune system of patients with SLE is a type I interferon (IFN) signature, which we recently also reported…
Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Hirotaka Yamada², Yoshihide Ichise², Ikuko Naka³, Yo Ueda², Takaichi Okano², Soshi Takahashi⁴, Kengo Akashi⁵, Akira Onishi⁶ and Akio Morinobu⁴, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].